BioSpace News Archive

Turbine and Harmonic Discovery have entered into a collaboration to co-develop novel cancer therapies that will inhibit a dark kinase identified for cancer dependency using Turbine’s Simulated Cell™ platform.

Carisma Therapeutics Inc. today announced the appointment of John Hohneker, M.D. to the Board of Directors.

Lutris Pharma announced the appointment Moshe “Mori” Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

Quince Therapeutics, Inc. today provided an update on the company’s development pipeline and reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Glaukos Corporation announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

Bruker Corporation has been selected as the Instrument Business Outlook ‘Company of the Year’ for 2023.

VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

Rakovina Therapeutics Inc will be hosting an informational webinar on Wednesday, April 3, 2024.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) by its partner Viatris Inc. (NASDAQ: VTRS).